A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients

BACKGROUND AND PURPOSE: Vandetanib is a promising anticancer targeted agent for treating advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer, malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic medullary thyroid cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Zijun, Yu, Shuang, Hong, Shubin, Cao, Xiaopei, Xiu, Lingling, Liao, Zhihong, Li, Yanbing, Xiao, Haipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920236/
https://www.ncbi.nlm.nih.gov/pubmed/27382300
http://dx.doi.org/10.2147/OTT.S96830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920236/
https://www.ncbi.nlm.nih.gov/pubmed/27382300
http://dx.doi.org/10.2147/OTT.S96830

Ejemplares similares